A mildly abnormal stress rubidium-82 PET MPI test is linked to a 2.3 times higher risk of cardiac death compared with a normal test, indicating that PET MPI screening can boost the accuracy of risk determination in patients with coronary disease, according to a study published in the Journal of the American College of Cardiology. The study reviewed outcomes from 7,061 patients at four centers. The evaluation of the extent of ischemia and scar added to cardiac death risk reclassification in one in every nine patients in the study who had clinical PET MPI, researchers said.
PET MPI boosts risk prediction in coronary disease
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan